PHARMACOLOGICAL TREATMENT OF RELAPSING REMITTING
MULTIPLE SCLEROSIS-WHERE ARE WE?
CARMEN ADELLA SIRBU1#, EMILIA FURDU-LUNGUT1#, CRISTINA FLORENTINA PLESA1#, ALINA CRENGUȚA NICOLAE2#*, CRISTINA MANUELA DRAGOI2#
1Central University Emergency Military Hospital “Carol Davila”, Department of Neurology, 134, Calea Plevnei Str., Bucharest, Romania
2University of Medicine and Pharmacy ”Carol Davila”, Faculty of Pharmacy, Department of Biochemistry, 6, Traian Vuia
Str., Bucharest, Romania
*corresponding author: alinanicolae29@gmail.com
#All authors have contributed equal contribution to this work.
Download Full Article

Abstract:
Multiple sclerosis is a chronic disease of the central nervous system, characterized by inflammation, demyelination and
neurodegeneration. The cause of the disease is not known, but the mechanism is assumed to be an auto-immune one. For the
disease occurrence, two conditions are necessary: genetic predisposition and certain environmental factors acting as
activating factors. The total costs of this disease are high, as it affects mainly young people aged 20 - 40, the evolution is
long, requiring medical care, expensive treatments, recovery, in parallel with the loss of productivity at a certain moment,
during the disease evolution. Thus, the interest for an efficient, affordable and safe medication is of high interest. Today, we
have two categories of drugs modifying the evolution of this diseases as well as guides of diagnosis and treatment that are
periodically changing, according to the results of the clinical studies and of evidence-based medicine. As such, we aimed at
pointing out the main approved to treat the relapsing- remitting form of multiple sclerosis (RRMS).

Top